Results 41 to 50 of about 286,222 (357)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

Frontiers in Immunology, 2023
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members.
Hong Zhou, Hong Zhou, Hong Zhou, Yipeng Ma, Yipeng Ma, Fenglan Liu, Fenglan Liu, Bin Li, Bin Li, Dongjuan Qiao, Dongjuan Qiao, Peigen Ren, Mingjun Wang, Mingjun Wang   +13 more
doaj   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source

Functional properties and sequence variation of HTLV-1 p13

Retrovirology, 2020
Human T cell leukemia virus type-1 (HTLV-1) was the first retrovirus found to cause cancer in humans, but the mechanisms that drive the development of leukemia and other diseases associated with HTLV-1 infection remain to be fully understood. This review
Maria Omsland, Micol Silic-Benussi, Ramona Moles, Sarkis Sarkis, Damian F. J. Purcell, David Yurick, Georges Khoury, Donna M. D’Agostino, Vincenzo Ciminale, Genoveffa Franchini   +9 more
doaj   +1 more source

mRNA vaccine in cancer therapy: Current advance and future outlook

Clinical and Translational Medicine, 2023
Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer.
Youhuai Li, Mina Wang, Xueqiang Peng, Yingying Yang, Qishuang Chen, Jiaxing Liu, Qing She, Jichao Tan, Chuyuan Lou, Zehuan Liao, Xuexin Li   +10 more
doaj   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Therapeutic cancer vaccines [PDF]

Journal of Clinical Investigation, 2015
The clinical benefit of therapeutic cancer vaccines has been established. Whereas regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in cancer patients was mostly noted as prolonged survival. Suboptimal vaccine design and an immunosuppressive cancer microenvironment are the root causes of the lack of cancer ...
Melief, C.J.M., Hall, T. van, Arens, R., Ossendorp, F., Burg, S.H. van der   +4 more
openaire   +3 more sources

Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Optical coherence tomography (OCT)‐derived retina measurements are markers for neuroaxonal visual pathway status. High‐quality OCT scans are essential for reliable measurements, but their acquisition is particularly challenging in eyes with severe visual impairment, as often observed in neuromyelitis optica spectrum disorders ...
Hadi Salih, Sara Samadzadeh, Charlotte Bereuter, Seyedamirhosein Motamedi, Claudia Chien, Pablo Villoslada, Hadas Stiebel‐Kalish, Nasrin Asgari, Yang Mao‐Draayer, Marius Ringelstein, Joachim Havla, Marco Aurélio Lana Peixoto, Ho Jin Kim, Jacqueline Palace, Maria Isabel Leite, Srilakshmi M. Sharma, Fereshteh Ashtari, Rahele Kafieh, Lekha Pandit, Orhan Aktas, Philipp Albrecht, Letizia Leocani, Itay Lotan, Sasitorn Siritho, Jérôme de Seze, Romain Marignier, Caroline Froment Tilikete, Denis Bernardi Bichuetti, Ivan Maynart Tavares, Ayse Altintas, Anu Jacob, Saif Huda, Ibis Soto de Castillo, Lawrence J. Cook, Michael R. Yeaman, Axel Petzold, Alexander U. Brandt, Friedemann Paul, Frederike C. Oertel, Hanna G. Zimmermann, with the Guthy Jackson Charitable Foundation—International Clinical Consortium and CROCTINO Collaborators   +40 more
wiley   +1 more source

Expression of HIV from a 1-LTR circular DNA in the absence of integration

Retrovirology
Background Like all retroviruses, two kinds of viral DNA are present in the nucleus of HIV-infected cells: integrated DNA and a pool of unintegrated DNA containing linear and circular forms. For the most part, it has been difficult to examine the role of
Corrado Gurgo, Claudio Fenizia, Katherine McKinnon, Ru-ching Hsia, Genoveffa Franchini   +4 more
doaj   +1 more source

Application of Nanotechnology in Therapeutic Cancer Vaccines

Advanced NanoBiomed Research, 2023
Cancer vaccines stimulate the immune system within the body by introducing tumor antigens in various forms, such as tumor cells, tumor‐related proteins or peptides, and genes expressing tumor antigens, into the body.
Jianmei Guo, Lin Tang, Kelin Li, Qingxin Ma, Shuda Luo, Ruoyu Cheng, Chaoyong Liu   +6 more
doaj   +1 more source

Lung Cancer Vaccines [PDF]

The Cancer Journal, 2011
To date, in lung cancer, early attempts to modulate the immune system via vaccine-based therapeutics have been unsuccessful. An improved understanding of tumor immunology has facilitated the production of more sophisticated lung cancer vaccines. It is anticipated that it will likely require multiple epitopes of a diverse set of genes restricted to ...
Ronan J, Kelly, Giuseppe, Giaccone
openaire   +2 more sources